Destiny Pharma conducts proprietary and contract research within the pharmaceutical R&D business sector. Their primary mission is to identify and develop patented therapeutic pharmaceutical technologies for exploitation by the pharmaceutical industry. Destiny Pharma have developed a revolutionary series of light activated, anti-bacterial drugs, (the XF drug series), which are potent against hospital 'superbugs' e.g. MRSA. They are currently raising funds to conduct clinical trials on the XF drugs for elimination of MRSA in hospital patients. Destiny Pharma has been successful in winning Smart and Craft Awards and has also raised significant investment capital for their research.